Acute Myocardial InfarctionNCT04544384
Acute Myocardial Infarction in Iceland, is There a Gender Difference in Treatment and Survival?
An observational study of Acute Myocardial Infarction and Coronary Angiography, run by Landspitali University Hospital.
Trial summary
All patients in Iceland with STEMI (2008-2018) and NSTEMI (2013-2018) that underwent coronary angiography and had obstructive coronary artery disease were included. Information about patients and angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Acute Myocardial Infarction, Coronary Angiography
- How many people
- 3,257 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2008to 1 Feb 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients, aged 18 years and older, who underwent coronary angiography for acute myocardial infarction (AMI) during the study period. All procedures were performed at Landspitali University Hospital, which is a tertiary referral center and the only institution performing coronary angiographies in Iceland. The study period was from January 1, 2008 to December 31, 2018 for ST elevation myocardial infarction (STEMI and from January 1, 2013 to December 31, 2018 for non-ST elevation myocardial infarction (NSTEMI).
Who may be able to join
- Patients with NSTEMI during 2013-2018 that underwent coronary angiography
- Patients with STEMI during 2008-2018 that underwent coronary angiography
Who cannot join
- Normal coronary arteries on coronary angiography
- Not first presentation of NSTEMI or STEMI during the study period
- Lost survival data
About this study
All patients in Iceland with STEMI (2008-2018) and NSTEMI (2013-2018) that underwent coronary angiography and had obstructive coronary artery disease were included. Information about patients and angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Survival was estimated with Kaplan-Meier method. Cox regression analysis were used to identify significant risk factors for long-term mortality. Relative survival was defined as observed survival divided by expected survival of the population of Iceland
Read the detailed description
Methods This is a retrospective observational nationwide study of all patients, aged 18 years and older, who underwent coronary angiography for acute myocardial infarction (AMI) during the study period. All procedures were performed at Landspitali University Hospital, which is a tertiary referral center and the only institution performing coronary angiographies in Iceland. The study period was from January 1, 2008 to December 31, 2018 for ST elevation myocardial infarction (STEMI and from January 1, 2013 to December 31, 2018 for non-ST elevation myocardial infarction (NSTEMI). For multiple admissions, the first was retained.
Information about patient demographics, cardiovascular risk factors, comorbidities, angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), a Swedish Web-based database also used in Iceland that prospectively record both patient- and procedure-related factors. All data are registered by the treating physician and nurses at the time of the procedure.
Clinical definitions Cases of acute myocardial were defined as STEMI and NSTEMI, according to the current European Society of Cardiology guidelines, and determined by the attending cardiologist [18]. The NSTEMI diagnosis was introduced into the database 2013 and there was also a change in the Troponin analysis used at that time. This is the reason why we chose to have a shorter study period for the NSTEMI patients. We excluded patients that had not significant coronary artery stenoses. Cardiovascular risk factors, including hypertension, diabetes mellitus, smoking status, statin use, body mass index (BMI) and renal function were recorded. Chronic kidney disease (CKD) was staged according to the Kidney Disease Outcome Quality Initiative (KDOQI) classification. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine measurements using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and CKD was defined as eGFR < 60 mL/min/1.73 m2 (stage 3-5).
Prior MI, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were recorded as defined in the database. Since these were AMI patients, they were all done urgently but it was also recorded whether they were done acutely as primary PCIs. The results of the coronary angiography were expressed as the number of vessels involved with significant stenoses or left main stem disease based on angiographic results. If PCI was performed, it was recorded whether patients received aspirin (acetylsalicylic acid) or adenosine diphosphate receptor (ADP) inhibitor before or during the procedure. The choice of treatment, medical therapy alone, PCI or CABG, was at the discretion of the attending interventional cardiologist and/or the heart team.
Observed and Expected Survival Data for all-cause mortality were extracted through linkage with Statistics Iceland. Patients were followed up for their vital status after hospitalization, with censoring at the end of follow-up on October 23, 2019. Expected survival was derived from the general population of Iceland matched to observed survival for the study population by sex, age and year of hospitalization.
Statistical analysis All calculations were performed using R software version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). All continuous variables were normally distributed and were compared with Student´s t-test and presented as mean ± standard deviation (SD). Categorical variables were compared using Chi-square test if the observed data was over five, otherwise Fisher´s Exact test was performed. Statistical significance was prespecified at 5% (P < 0.05) Kaplan-Meier curve was plotted to assess the estimated long-term survival and the two groups were compared using a log-rank test. To identify independent prognostic factors for survival, a Cox multivariate analysis was used, represented as hazard ratios with 95% confidence intervals.
Relative survival was defined as the observed survival among patients with AMI divided by expected survival in populace of Iceland matched by sex, age and year.
As individual patients were not identified, obtaining individual consent for the study was not obtained.
- Conditions
- Acute Myocardial Infarction, Coronary Angiography
- Keywords
- Acute myocardial infarction, Gender difference, Long-term survival, Excess mortality
What is being measured
The primary outcome is the main question the study is designed to answer.
Long-term Survival
Compare treatment and survival of men and women with NSTEMI or STEMI and obstructive coronary artery disease.
Measured: From time of NSTEMI/STEMI to mortality or October 23, 2019
Secondary outcomes (2)
Independent risk factors for mortality
Independent risk factors for mortality are found by Cox regression analysis
Measured: For NSTEMI (2013-2018) and For STEMI (2008-2018)
Relative survival
Defined as observed survival, among patients with STEMI and NSTEMI, divided by expected survival in the matched populace of Iceland.
Measured: For NSTEMI (2013-2018) and For STEMI (2008-2018)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2020
- Study start1 Jan 2008
- Primary completion1 Feb 2020
- Study completion1 Feb 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 3,257 participants (actual)
Sponsor and investigators
- Lead sponsor
- Landspitali University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Statistics Iceland
- Responsible party
- Sponsor
- Investigators
- Ingibjorg Gudmundsdottir, Phd, MD, Study director, Landspitali
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04544384
- Sponsor's protocol ID
- LSH-19-003
- Status last verified
- Sep 2020
- First submitted
- 2 Sep 2020
- Last updated
- 10 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Myocardial Infarction in Iceland, is There a Gender Difference in Treatment and Survival?
- ClinicalTrials.gov ID
- NCT04544384
- Acronym / sponsor ID
- LSH-19-003
- Conditions
- Acute Myocardial Infarction, Coronary Angiography
- Keywords
- Acute myocardial infarction, Gender difference, Long-term survival, Excess mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,257 participants (actual)
- Lead sponsor
- Landspitali University HospitalUniversity, hospital or other
- Collaborators
- Statistics Iceland
- Study start
- 1 Jan 2008 (actual)
- Primary completion
- 1 Feb 2020 (actual)
- Study completion
- 1 Feb 2020 (actual)
- First posted
- 10 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All patients in Iceland with STEMI (2008-2018) and NSTEMI (2013-2018) that underwent coronary angiography and had obstructive coronary artery disease were included. Information about patients and angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Survival was estimated with Kaplan-Meier method. Cox regression analysis were used to identify significant risk factors for long-term mortality. Relative survival was defined as observed survival divided by expected survival of the population of Iceland
Detailed description
Methods This is a retrospective observational nationwide study of all patients, aged 18 years and older, who underwent coronary angiography for acute myocardial infarction (AMI) during the study period. All procedures were performed at Landspitali University Hospital, which is a tertiary referral center and the only institution performing coronary angiographies in Iceland. The study period was from January 1, 2008 to December 31, 2018 for ST elevation myocardial infarction (STEMI and from January 1, 2013 to December 31, 2018 for non-ST elevation myocardial infarction (NSTEMI). For multiple admissions, the first was retained.
Information about patient demographics, cardiovascular risk factors, comorbidities, angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), a Swedish Web-based database also used in Iceland that prospectively record both patient- and procedure-related factors. All data are registered by the treating physician and nurses at the time of the procedure.
Clinical definitions Cases of acute myocardial were defined as STEMI and NSTEMI, according to the current European Society of Cardiology guidelines, and determined by the attending cardiologist [18]. The NSTEMI diagnosis was introduced into the database 2013 and there was also a change in the Troponin analysis used at that time. This is the reason why we chose to have a shorter study period for the NSTEMI patients. We excluded patients that had not significant coronary artery stenoses. Cardiovascular risk factors, including hypertension, diabetes mellitus, smoking status, statin use, body mass index (BMI) and renal function were recorded. Chronic kidney disease (CKD) was staged according to the Kidney Disease Outcome Quality Initiative (KDOQI) classification. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine measurements using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and CKD was defined as eGFR < 60 mL/min/1.73 m2 (stage 3-5).
Prior MI, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were recorded as defined in the database. Since these were AMI patients, they were all done urgently but it was also recorded whether they were done acutely as primary PCIs. The results of the coronary angiography were expressed as the number of vessels involved with significant stenoses or left main stem disease based on angiographic results. If PCI was performed, it was recorded whether patients received aspirin (acetylsalicylic acid) or adenosine diphosphate receptor (ADP) inhibitor before or during the procedure. The choice of treatment, medical therapy alone, PCI or CABG, was at the discretion of the attending interventional cardiologist and/or the heart team.
Observed and Expected Survival Data for all-cause mortality were extracted through linkage with Statistics Iceland. Patients were followed up for their vital status after hospitalization, with censoring at the end of follow-up on October 23, 2019. Expected survival was derived from the general population of Iceland matched to observed survival for the study population by sex, age and year of hospitalization.
Statistical analysis All calculations were performed using R software version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). All continuous variables were normally distributed and were compared with Student´s t-test and presented as mean ± standard deviation (SD). Categorical variables were compared using Chi-square test if the observed data was over five, otherwise Fisher´s Exact test was performed. Statistical significance was prespecified at 5% (P < 0.05) Kaplan-Meier curve was plotted to assess the estimated long-term survival and the two groups were compared using a log-rank test. To identify independent prognostic factors for survival, a Cox multivariate analysis was used, represented as hazard ratios with 95% confidence intervals.
Relative survival was defined as the observed survival among patients with AMI divided by expected survival in populace of Iceland matched by sex, age and year.
As individual patients were not identified, obtaining individual consent for the study was not obtained.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients, aged 18 years and older, who underwent coronary angiography for acute myocardial infarction (AMI) during the study period. All procedures were performed at Landspitali University Hospital, which is a tertiary referral center and the only institution performing coronary angiographies in Iceland. The study period was from January 1, 2008 to December 31, 2018 for ST elevation myocardial infarction (STEMI and from January 1, 2013 to December 31, 2018 for non-ST elevation myocardial infarction (NSTEMI).
Key inclusion criteria (2 listed)
- Patients with NSTEMI during 2013-2018 that underwent coronary angiography
- Patients with STEMI during 2008-2018 that underwent coronary angiography
Key exclusion criteria (3 listed)
- Normal coronary arteries on coronary angiography
- Not first presentation of NSTEMI or STEMI during the study period
- Lost survival data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Long-term Survival
Time frame: From time of NSTEMI/STEMI to mortality or October 23, 2019
Compare treatment and survival of men and women with NSTEMI or STEMI and obstructive coronary artery disease.
2 secondary outcomes
Independent risk factors for mortality
Time frame: For NSTEMI (2013-2018) and For STEMI (2008-2018)
Relative survival
Time frame: For NSTEMI (2013-2018) and For STEMI (2008-2018)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2020.
Related trials for Acute Myocardial Infarction
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ingibjorg Gudmundsdottir, Phd, MD study director
Landspitali
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction and Coronary Angiography, run by Landspitali University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Long-term Survival (time frame: From time of NSTEMI/STEMI to mortality or October 23, 2019). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2020.